75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Nature of the Business
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Prepaid Expenses and Other Current Assets
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Property and Equipment
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Accrued Expenses
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Debt
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - License Agreement, Advances From Collaboration Partners, Legal and Other Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Stockholders' Deficit
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Stock-based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Recurring Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Other (Income) Expense, Net
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Segment and Geographic Information
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Net Loss Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Merger Accounting
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Property and Equipment (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Accrued Expenses (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Stockholders' Deficit (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Stock-based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Recurring Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Other (Income) Expense, Net (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Segment and Geographic Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Net Loss Per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Merger Accounting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Nature of the Business - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Prepaid Expenses and Other Current Assets (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Accrued Expenses - Accrued Expenses (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Debt - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Debt - Schedule of Future Principal Payments for Long-Term Debt (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Debt - Schedule of Future Principal Payments for Long-Term Debt (Detail) 2
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - License Agreement, Advances From Collaboration Partners, Legal and Other Contingencies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Stockholders' Deficit - Schedule of Transactions Related to Warrants (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Stockholders' Deficit - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Stock-based Compensation - Transactions Related to Stock Options Awarded to Employees and Directors (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Stock-based Compensation - Activity Related to Restricted Stock Units Awarded to Employees (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Stock-based Compensation - Summary of Allocated Stock-based Compensation Expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Stock-based Compensation (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Recurring Fair Value Measurements - Schedule of Assets and liabilities measured at fair value on a recurring basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Recurring Fair Value Measurements - Schedule of the Fair Value of the Warrant Derivative Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Recurring Fair Value Measurements - Summary of the fair value of the derivative liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Recurring Fair Value Measurements (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Other (Income) Expense, Net - Schedule of Other (income) expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Segment and Geographic Information (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Segment Information - Schedule of CODM expense categories (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Net Loss Per Share - Schedule of Net Loss and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Loss Per Share (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Net Loss Per Share (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Merger Accounting - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Merger Accounting - Summary of Total Consideration for Merger (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Merger Accounting - Summary of Purchase Price Allocation (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Subsequent Events (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Unbilled receivable
Increase (Decrease) in Unbilled Receivables
Unbilled receivable
Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Line of Credit Facility, Increase, Accrued Interest
Accrued interest
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchase in Period
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchase in Period
Repurchased
Preferred Stock, Shares Issued
Preferred stock, shares issued
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accounts Payable, Total
Patent expenses due to Harvard
Patent Expenses Due To Harvard
Patent Expenses Due To Harvard
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Noncash financing activities:
Long-Term Debt, Excluding Current Maturities
Long-term debt, net of current portion
Long-term portion
Long-Term Debt, Excluding Current Maturities, Total
Plan Name [Axis]
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Classification [Domain]
Classification [Domain]
Proceeds from Warrant Exercises
Proceeds from warrant exercises
Issuance Date
Debt Instrument, Issuance Date
Operating Expenses [Abstract]
Operating expenses:
Fair Value, Inputs, Level 2 [Member]
Level 2 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price
Common Stock, Shares Authorized
Common stock, shares authorized
Share-Based Payment Arrangement, Tranche Three [Member]
Third Tranche [Member]
Product and Service [Axis]
Document Fiscal Period Focus
Document Fiscal Period Focus
Debt Instrument, Interest Rate, Stated Percentage
Promissory note interest rate
Entity Shell Company
Entity Shell Company
Other Accrued Liabilities, Current
Other
Cash and Cash Equivalent
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Cash and cash equivalents
Schedule of Maturities of Long-Term Debt [Table Text Block]
Schedule of Future Principal Payments for Long-Term Debt
Offering Price Per Underlying Share
Offering Price Per Underlying Share
Long-Duration Contracts, Assumptions by Product and Guarantee, Volatility Rate
Volatility
Two Thousand Nineteen Cystic Fibrosis Foundation Award [Member]
Two Thousand Nineteen Cystic Fibrosis Foundation Award [Member]
Two Thousand Nineteen Cystic Fibrosis Foundation Award [Member]
Adjusted for a discount for lack of marketability percentage.
Adjusted For Discount For Lack Of Marketability Percentage
Adjusted for a discount for lack of marketability ("DLOM"), percentage
Common Stock, Shares, Issued
Common stock, shares issued
Statement [Table]
Statement [Table]
Debt instrument repayment, number of installments.
Debt Instrument Repayment Number Of Installments
Loan, number of repayment installments
Bridge Loans [Member]
Bridge Loans [Member]
Tranche 2 Advance [Member]
Tranche Two Advance [Member]
Tranche two advance.
Share Repurchase Program, Remaining Authorized, Number of Shares
Shares remaining and available for issuance
Statement [Line Items]
Statement [Line Items]
Change in fair value of derivative liabilities
Change In Fair Value Of Derivative Liabilities
Change In Fair Value Of Derivative Liabilities
Business Combination [Domain]
Business Acquisition, Acquiree
Warrant [Member]
Common warrants [Member]
Entity Filer Category
Entity Filer Category
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Amount
Liabilities and Equity
Total liabilities and stockholders' equity (deficit)
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Payables and Accruals [Abstract]
Long-Term Debt, Current Maturities
Long-Term Debt, Current Maturities, Total
Less current portion of long-term debt
Current portion of long-term debt
Long-Term Debt, Maturity, Year Three
2025
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Options exercisable at June 30, 2026
Debt Instrument, Frequency of Periodic Payment
Loan, frequency of periodic payment
Debt Instrument, Date of First Required Payment
Loan, periodic principal and interest payment commencement date
Cash and Cash Equivalents, Fair Value Disclosure
Cash and Cash Equivalents
Subsequent Event [Line Items]
License and Service [Member]
License and Service Revenue [Member]
Effective cash balance
Effective cash balance
Minimum qualified cash balance
Minimum Qualified Cash Balance
Minimum qualified cash balance.
Advances from Collaboration Partners Current
Advances from Collaboration Partners Current
Advances from collaboration partners, net of debt discount
Additional paid-in capital
Additional Paid in Capital, Common Stock
Additional paid-in capital
Tranche 3 Advance [Member]
Tranche Three Advance [Member]
Tranche three advance.
Debt Conversion Principal Amount
Debt Conversion, Principal Debt, Amount
Debt Conversion, Principal Debt, Amount
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Coastlands Securities Agreement [Member]
Coastlands Securities Agreement Member
Coastlands [Member]
Vesting [Domain]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Granted
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Schedule of Net Loss and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Loss Per Share
Paycheck protection program loan.
Paycheck Protection Program Loan [Member]
PPP Loan [Member]
Accrued research and development expense current.
Accrued Research And Development Expense Current
Research and development
Liability
Liability [Member]
Investment, Name [Axis]
Earnings Per Share, Basic
Net loss per share, basic
Net loss per share, basic
Earnings Per Share, Basic, Total
Repayments of Long-Term Debt
Repayments of Long-Term Debt, Total
Loan repayment
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Options outstanding at December 31, 2025
Options outstanding at June 30, 2026
Liabilities, Current
Total current liabilities
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Class of Warrant Purchase Price
Class of Warrant Purchase Price
Class of warrant purchase price
Unpaid interest
Waive Additional Accrued and Unpaid Interest Related
Waive Additional Accrued and Unpaid Interest Related
Class of warrant or right expiration period.
Class Of Warrant Or Right Expiration Period
Weighted average remaining contractual life
Term (years)
Consolidation Items [Domain]
Initial loan.
Initial Loan [Member]
Initial Loan [Member]
Equity, Attributable to Parent [Abstract]
Stockholders' equity (deficit):
Entity Small Business
Entity Small Business
Increase (Decrease) in Accrued Liabilities
Accrued expenses
Increase (Decrease) in Accrued Liabilities, Total
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Forfeited
Proceeds from Issuance Initial Public Offering
Proceeds from the June 2026 public offering, net of issuance costs
Net proceeds from the public offering
Sale of Stock, Price Per Share
Stock Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value
Aggregate intrinsic value Exercised
Share-Based Payment Arrangement [Text Block]
Stock-based Compensation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Increase (Decrease) in License fee receivable
Increase (Decrease) in License fee receivable
License fee receivable
Total Gross Proceeds
total gross proceeds
total gross proceeds
Amendment Flag
Amendment Flag
Product and Service [Domain]
Chief Executive Officer [Member]
Liabilities and Equity [Abstract]
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash (used in) provided by operating activities
Fair value of warrant liabilities.
Fair Value Of Warrant Liabilities
Fair value of warrant liabilities, beginning of period
Fair value of warrant liabilities, beginning of period
Fair value of warrant liabilities, end of period
Restricted stock vested during period shares.
Restricted Stock Vested During Period Shares
Vesting of restricted stock units, shares
Pre-Funded Warrants [Member]
Pre-Funded Warrants [Member]
Pre-Funded Warrants
Common Stock [Member]
Common Stock [Member]
Long-Term Debt, Maturity, Year One
2023
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Granted
Other Operating Income (Expense), Net
Other expense, net
Amortization of Debt Discount (Premium)
Amortization of debt discount
Class Of warrant or right exercisable expiration period.
Class Of Warrant Or Right Exercisable Expiration Period
Warrants exercisable, Weighted average remaining contractual life
Debt Instrument, Interest Rate, Effective Percentage
Loan, effective interest rate
Entity Address, Address Line One
Entity Address, Address Line One
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV
Earnings Per Share [Abstract]
Denominator:
Earnings per share basic and diluted disclosures abstract.
Earnings Per Share Basic And Diluted Disclosures [Abstract]
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow activities:
Restricted Stock Awards [Member]
Restricted Stock Awards [Member]
Restricted Stock Awards [Member]
Cystic fibrosis foundation.
Cystic Fibrosis Foundation [Member]
Cystic Fibrosis Foundation [Member]
Document Type
Document Type
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Summary of Warrants Outstanding
Schedule Of Warrant Activity Table [Text Block]
Schedule of warrant activity.
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Entity Central Index Key
Entity Central Index Key
Long term debt maturities final fee due.
Long Term Debt Maturities Final Fee Due
Loan, final maturity payment
Final fee due at maturity in 2023
Valuation Approach and Technique [Axis]
Valuation Approach and Technique
Decrease in cash, cash equivalents and restricted cash
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Increase in cash, cash equivalents and restricted cash
Subsequent Event Type [Domain]
Change in fair value of warrant liabilities
Fair Value Adjustment of Warrants
Net of initial common warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Total potential common stock equivalents
Schedule of prepaid expense and other current assets.
Schedule Of Prepaid Expense And Other Current Assets Table [Text Block]
Prepaid Expenses and Other Current Assets
Common Stock, Par or Stated Value Per Share
Common stock, par value
January 2024 Pre-Funded Warrant [Member]
January 2024 Pre-Funded Warrant [Member]
January 2024 Pre-Funded Warrant
Proceeds from Issuance of Warrants
Issuance of 2023 Common Warrants and Placement Agent Warrants
Net income loss available to common stockholders basic and diluted.
Net Income Loss Available To Common Stockholders Basic And Diluted [Abstract]
Numerator:
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Options outstanding
Remaining amount of award payable upon achievement certain clinical development milestones
Remaining Amount Of Award Payable Upon Achievement Certain Clinical Development Milestones
Remaining amount of award payable upon achievement certain clinical development milestones.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Exercise of stock options, shares
Exercised
Other Prepaid Expense, Current
Other
Debt Disclosure [Abstract]
Accrued Liabilities, Current
Accrued expenses
Total
December Two Thousand Twenty Five Pre Funded Warrant [Member]
December Two Thousand Twenty Five Pre Funded Warrant [Member]
December 2025 Pre-Funded Warrant
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Current Fiscal Year End Date
Current Fiscal Year End Date
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Table]
Legal Matters and Contingencies [Text Block]
License Agreement, Advances From Collaboration Partners, Legal and Other Contingencies
Document Quarterly Report
Document Quarterly Report
Business combination, recognized identifiable assets acquired and liabilities assumed accrued expenses.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expenses
Accrued expenses
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Repurchase Fair Value
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Repurchase Fair Value
Repurchased
Entity Address, State or Province
Entity Address, State or Province
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Unvested at December 31, 2025
Unvested at June 30, 2026
Purchase Price Per Share
Purchase Price Per Share
Purchase price per share
Company Received The Cash
Company Received The Cash
Investment, Name [Domain]
Business Combination [Table Text Block]
Summary of Total Consideration for Merger
Preferred Stock, Shares Outstanding
Preferred Stock, shares outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Plus Prime Rate
Plus Prime Rate
Plus Prime Rate
Common Stock, Capital Shares Reserved for Future Issuance
Number of shares of common stock reserved
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member]
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member]
Two Thousand Twenty Two Cystic Fibrosis Foundation Agreement [Member]
Class Of Warrant Or Right Expiration Period Minimum
Class Of Warrant Or Right Expiration Period Minimum
Term (years) Minimum
Increase (Decrease) in Accrued Interest Receivable, Net
Accrued interest
Term (years) Maximum
Class Of Warrant Or Right Expiration Period Maximum
Class Of Warrant Or Right Expiration Period Maximum
Imputed Interest
Imputed Interest
Imputed Interest
Payments for Royalties
Royalties
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Summary of Allocated Stock-based Compensation Expense
Stock Issued During Period, Value, Stock Options Exercised
Exercise of stock options
Exercise of stock options
February Two Thousand Twenty Six Pre Funded Warrant [Member]
February Two Thousand Twenty Six Pre Funded Warrant [Member]
February 2026 Pre-Funded Warrants
Interest income
Interest and Other Income
Loan, prepayment fee percentage
Debt Instrument Final Payment Fee Percentage
Debt instrument final payment fee percentage.
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Abstract]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value [Abstract]
Aggregate intrinsic value
Subsequent Event [Member]
Long-Term Debt, Maturity, Remainder of Fiscal Year
2022
Issuance of pre-funded warrants under the Coastlands and Domicilium Securities Purchase Agreements, net of issuance costs of $9k
Issuance of Pre-funded Warrants Under the Coastlands and Domicilium Securities Purchase Agreements, Net of Issuance Costs
Issuance of Pre-funded Warrants Under the Coastlands and Domicilium Securities Purchase Agreements, Net of Issuance Costs
Property, Plant and Equipment [Abstract]
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]
August Two Thousand Twenty Five Pre Funded Warrant [Member]
August Two Thousand Twenty Five Pre Funded Warrant [Member]
August 2025 Pre-Funded Warrant
Antidilutive Securities [Axis]
Antidilutive Securities
Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current
Prepaid expenses and other current assets
Interest Expense, Debt
Loan, interest expense
Interest Expense, Debt, Total
Debt Instrument, Unamortized Discount
Loan, unamortized debt discount
Less unamortized discount
Debt Instrument, Unamortized Discount, Total
Unamortized debt discount
Related Party Transaction [Axis]
Treasury Stock, Common, Shares
Common stock, treasury shares
Cash and Cash Equivalents [Domain]
Award to fund development milestones
Award To Fund Development Milestones Amount
Award to fund development milestones amount.
Business Combination, Consideration Transferred
Total purchase price
Business Combination, Consideration Transferred, Total
Preferred Stock, Value, Issued
Preferred stock, $0.01 par value per share, 5,000,000 shares authorized, no shares issued or outstanding as of June 30, 2026 and December 31, 2025
Business Combination, Consideration Transferred, Equity Interest, Share Issued, Value
Adjusted for a discount for lack of marketability ("DLOM")
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill
Intangible assets
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total
Debt Instrument, Maturity Date
Loan, maturity date
Minimum [Member]
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Granted
Gain on imputed interest on bridge loans
Gain On Imputed Interest On Bridge Loans
Gain On Imputed Interest On Bridge Loans
Assets, Current [Abstract]
Current assets:
Interest expense
Interest Expense, Other
Fair Value, Inputs, Level 3 [Member]
Level 3 [Member]
Business acquisition transaction costs.
Business Acquisition Transaction Costs
Transaction costs
Segment Reporting [Abstract]
Business Combination, Recognized Asset Acquired, Asset
Total Assets
Schedule of Assets and liabilities measured at fair value on a recurring basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Liabilities, Current [Abstract]
Current liabilities:
Stock Repurchased and Retired During Period, Value
Effect due to reverse stock split
Royalty payment percentage on net sales.
Royalty Payment Percentage On Net Sales
Royalty payment as percentage of net sales
Restricted Cash and Cash Equivalent
Restricted cash
Restricted Cash and Cash Equivalents, Total
Commitments and Contingencies
Commitments and contingencies
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Unvested at December 31, 2025
Unvested at June 30, 2026
Share-based compensation arrangement by share-based payment award exercisable period of vested options.
Share Based Compensation Arrangement By Share Based Payment Award Exercisable Period Of Vested Options
Exercisable period of vested options
General and Administrative Expense [Member]
General and Administrative Expense [Member]
September 2025 Pre-Funded Warrant
September Two Thousand Twenty Five Pre Funded Warrant [Member]
September Two Thousand Twenty Five Pre Funded Warrant [Member]
Debt Instrument, Basis Spread on Variable Rate
Loan, floating interest rate
Stockholders' Equity, Reverse Stock Split
Common stock, Reverse stock split
Issuance of pre-funded warrants related to the September 2025 Domicilium debt conversion per agreement
Issuance of pre-funded warrants related to the September 2025 Domicilium debt conversion per agreement
Issuance of pre-funded warrants related to the February 2026 Domicilium debt conversion
January 2024 Common Stock Warrant
January 2024 Common Stock Warrant [Member]
January 2024 Common Stock Warrant [Member]
Restricted Cash, Current
Restricted cash
Long-Term Debt, Maturity, Year Two
2024
Additional cash received
Derivative, Cash Received on Hedge
Coastlands and Domicilium [Member]
Coastlands and Domicilium [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted Intrinsic Value
Aggregate intrinsic value Granted
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent
Cash and cash equivalents
Long-Term Debt, Type [Domain]
Long-Term Debt, Type
Loss Contingencies [Table]
Weighted Average Number of Shares Outstanding, Basic
Weighted average number of shares of common stock used in computing net loss per share, basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, basic
Sale of stock, authorized amount of common stock
Sale Of Stock Authorized Amount Of Common Stock
Sale of stock, authorized amount of common stock.
Two Thousand Twenty Five Cystic Fibrosis Foundation Agreement [Member]
Two Thousand Twenty Five Cystic Fibrosis Foundation Agreement [Member]
2025 CFF Award [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Options exercisable
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Stock Issued During Period, Shares, Reverse Stock Splits
Reclassification due to reverse stock split, shares
Effect due to reverse stock split, shares
Monte Carlo Simulation [Member]
Monte Carlo Simulation [Member]
Monte Carlo Simulation [Member]
Subsequent Events [Text Block]
Subsequent Events
Long-Term Debt
Aggregate principal amount of initial loan advance
Carrying value of long-term debt
Aggregate principal amount of initial loan advance
Prepaid Deferred Offering Costs
Prepaid Deferred Offering Costs
Deferred offering costs
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation expense
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Two Thousand Twenty One Cystic Fibrosis Foundation Award
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member]
Two Thousand Twenty One Cystic Fibrosis Foundation Award [Member]
Percentage of sales agents commission on gross proceeds of sales of common stock.
Percentage Of Sales Agents Commission On Gross Proceeds Of Sales Of Common Stock
Percentage of sales agents commission
Equity, Attributable to Parent
Balance
Balance
Total stockholders' equity (deficit)
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Exercise of pre-funded warrants
Exercise of pre-funded warrants
Exercise of pre-funded warrants
Statement of Stockholders' Equity [Abstract]
Other research and development
Research and Development Expense, Software (Excluding Acquired in Process Cost)
Valuation Approach and Technique [Domain]
Valuation Approach and Technique
Black-Scholes Models [Member]
Black-Scholes Models [Member]
Black-Scholes Models [Member]
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment
Property and equipment
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total
Treasury Stock, Common [Member]
Treasury Stock [Member]
Entity Address, Address Line Two
Recurring Fair Value Measurements
Fair Value Disclosures [Text Block]
Share-based compensation arrangements by share based payment award options grants in period contractual life.
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Contractual Life
Contractual life of stock options granted
Warrants and Rights Note Disclosure [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Amount
Schedule of Accrued Liabilities [Table Text Block]
Accrued expenses
Debt Instrument, Name [Domain]
Debt Instrument, Name
Prepaid research and development current.
Prepaid Research And Development Current
Research and development
Plan Name [Domain]
Payments for Merger Related Costs
Incurred and expensed costs related to merger
Merger related costs paid
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investment, Ownership Percentage
Percentage ownership
Class of Warrant or Right, Outstanding
Pre-Funded Common Warrants
Warrants Outstanding
Upfront payment received
Upfront Payment Received
Upfront payment received.
Related and Nonrelated Parties [Axis]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]
June Two Thousand Twenty Six Pre Funded Warrant [Member]
June Two Thousand Twenty Six Pre Funded Warrant [Member]
June 2026 Pre-Funded Warrants
Entity Address, City or Town
Entity Address, City or Town
Israel Innovation Authority [Member]
Israel Innovation Authority [Member]
Israel Innovation Authority [Member]
Number of Reportable Segments
Security Exchange Name
Security Exchange Name
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction
Issuance costs in accounts payable and accrued expenses
Stock subscription receivable
Stock Subscription Receivable
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable
Business Combination, Date of Acquisition Agreement
Date of acquisition
Long-Term Debt, Gross
Loan, principal outstanding
Total future principal payments
Aggregate milestone payment
Aggregate Amount Of Milestone Payment
Aggregate amount of milestone payment.
Deferred Offering Costs
Deferred offering costs
Clinical and regulatory milestone payments received.
Clinical And Regulatory Milestone Payments Received
Clinical and regulatory milestone payments received
Paycheck Protection Program loan proceeds.
Paycheck Protection Program Loan Proceeds
PPP Loan proceeds received
Second Quarter 2026 Equity Activity [Member]
Second Quarter 2026 Equity Activity [Member]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name
Debt Instrument, Increase, Accrued Interest
Debt Instrument accrued interest
Interest Paid, Excluding Capitalized Interest, Operating Activity
Cash paid for interest
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Statistical Measurement [Domain]
Statistical Measurement
Domicilium Term Loan [Member]
Domicilium Term Loan [Member]
Domicilium Term Loan [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights
Weighted average exercise price
Exercise Price
Assets, Current
Total current assets
Share-Based Payment Arrangement, Expense
Stock-based compensation expense
Document Period End Date
Document Period End Date
Contingent liability related to grants received royalties payable including accrued LIBOR interest.
Contingent Liability Related To Grants Received Royalties Payable Including Accrued L I B O R Interest
Royalty received including accrued LIBOR interest
Other Income and Expenses [Abstract]
Title and Position [Axis]
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Options exercisable at June 30, 2026
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units [Member]
Restricted stock units, unvested portion [Member]
Antidilutive Security, Excluded EPS Calculation [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Zikani Therapeutics Inc.
Zikani Therapeutics Inc [Member]
Zikani Therapeutics, Inc. [Member]
Vesting [Axis]
Net of initial common warrant liability
Warrant Liability
Warrant Liability
Milestone Payments
Milestone Payments
Milestone payments
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
Granted
Restricted Stock [Member]
Restricted stock awards [Member]
Restricted stock awards, unvested portion [Member]
Weighted Average Number of Shares Outstanding, Diluted
Weighted average number of shares of common stock used in computing net loss per share, diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, diluted
Securities Act File Number
Entity File Number
Cover [Abstract]
Significant CODM expense categories
Significant Expense Categories [Table Text Block]
Significant Expense Categories [Table Text Block]
Net cash proceeds
Net cash proceeds
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Total
Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Loss on Issuance of Common Stock
Loss on Issuance of Common Stock
Loss on issuance of common stock
Number of Operating Segments
Sale of Stock [Domain]
Segment and Geographic Information
Segment Reporting Disclosure [Text Block]
General and Administrative Expense
General and administrative
General and Administrative Expense, Total
Options to purchase common stock.
Options To Purchase Common Stock [Member]
Options to Purchase Common Stock [Member]
Share Based Compensation Arrangement by Share Based Payment Award Options Forfeited in Period Intrinsic Value
Share Based Compensation Arrangement by Share Based Payment Award Options Forfeited in Period Intrinsic Value
Aggregate intrinsic value Forfeited
Subsequent Event [Table]
Business Combination, Recognized Liability Assumed, Accounts Payable, Current
Accounts payable
Conversion Price
Debt Instrument, Convertible, Conversion Price
September 2023 Placement Agent Warrants
September 2023 Placement Agent Warrants [Member]
September 2023 Placement Agent Warrants [Member]
Loss on debt extinguishment
Gain (Loss) on Extinguishment of Debt
Gain (loss) on extinguishment of debt
Gain (Loss) on Extinguishment of Debt, Total
Gain on extinguishment of accrued interest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining contractual life
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
Activity Related to Restricted Stock Units Awarded to Employees
Royalties Percentage Of Net Sales Based On Actual Amount Of Funding
Royalties Percentage Of Net Sales Based On Actual Amount Of Funding
Royalties percentage of net sales based on actual amount of funding
Technion Research and Development Foundation Ltd.
Technion Research And Development Foundation Ltd [Member]
Technion Research and Development Foundation Ltd [Member]
Equity [Member]
Equity
Business Combination, Recognized Liability Assumed, Liability
Total liabilities
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-Free Rate Minimum
Proceeds from Issuance of Long-Term Debt, Total
Proceeds from Issuance of Long-Term Debt
Proceeds from debt financing obligations
Business combination recognized identifiable assets acquired assumed, in progress research and development.
Business Combination Recognized Identifiable Assets Acquired Assumed In Progress Research And Development
In process research and development acquired
Common Stock, Shares, Outstanding
Balance, shares
Balance, shares
Common stock, shares outstanding
Business combination, recognized identifiable assets acquired and liabilities, assumed restricted cash.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash
Restricted cash
Document Transition Report
Document Transition Report
Operating Expenses
Total operating expenses
Common Stock, Offered Share
Common Stock, Offered Share
Common Stock Offered Share
Placement Agent Warrants [Member]
Placement Agent Warrants [Member]
Placement Agent Warrants [Member]
Total research and development
Research and Development Expense
Research and development expense
Statement of Cash Flows [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value price
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Transactions Related to Stock Options Awarded to Employees and Directors
Equity [Text Block]
Stockholders' Deficit
Earnings Per Share [Text Block]
Net Loss Per Share
Net loss
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Options outstanding
Options outstanding, Beginning Balance
Options outstanding Ending Balance
Warrant liabilities
Warrant liabilities
Warrant liabilities
Two thousand and eighteen plan.
Two Thousand And Eighteen Plan [Member]
2018 Plan [Member]
First Quarter 2026 Equity Activity [Member]
First Quarter 2026 Equity Activity [Member]
Assets [Abstract]
ASSETS
Research and Development Arrangement [Member]
Research and Development Arrangement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-Free Rate
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other assets
Prepaid expenses and other current assets
Document Fiscal Year Focus
Document Fiscal Year Focus
Accounts Payable, Current
Accounts payable
Accounts Payable, Current, Total
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total
Value of the embedded derivative
Research and Development Expense [Member]
Research and Development Expense [Member]
Maximum repayment percentage of grants received from office of chief scientist.
Maximum Repayment Percentage Of Grants Received From Office Of Chief Scientist
Repayment percentage of grants received
Exercise Warrant During Pre-Funded Warrants
Exercise Warrant During Pre-Funded Warrants
Exercise of pre-funded warrants, shares
Principal amount
Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security
Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security, Total
Proceeds from Stock Options Exercised
Exercise of stock options
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Embedded Derivative, Fair Value of Embedded Derivative Liability
Fair value of derivative liabilities, beginning of period
Fair value of derivative liabilities, end of period
Restricted stock vested during period value.
Restricted Stock Vested During Period Value
Vesting of restricted stock units
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
Net assets acquired
Debt Instrument
Debt Instrument [Axis]
Classification [Axis]
Classification [Axis]
Share-Based Payment Arrangement [Abstract]
Sale of Stock [Axis]
Revenues
Revenues, Total
Revenue from related party
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Forfeited
Money Market Funds [Member]
Money Market Funds [Member]
Related and Nonrelated Parties [Domain]
Class of Warrant or Right [Line Items]
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Property and equipment, net
Property, Plant and Equipment [Table Text Block]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Options outstanding at December 31, 2025
Options outstanding at June 30, 2026
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Measurement Frequency [Domain]
Statement of Income Location, Balance [Axis]
Income Statement Location
Trading Symbol
Trading Symbol
Property, Plant and Equipment Disclosure [Text Block]
Property and Equipment
Risk-Free Rate Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Subsequent Event Type [Axis]
Employee-related Liabilities, Current
Payroll and other employee-related expenses
Employee-related Liabilities, Current, Total
Cash flows from financing activities:
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Fair Value, Recurring [Member]
Fair Value, Recurring [Member]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Accrued Expenses
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Deferred Offering Costs
Deferred Policy Acquisition Costs, Policy [Policy Text Block]
Equity Components [Axis]
Equity Components
Research and Development Expense (Excluding Acquired in Process Cost)
Research and development
Clinical and manufacturing
Equity Component [Domain]
Equity Component
Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]
Summary of Purchase Price Allocation
Business Combination [Axis]
Business Acquisition
Prepaid Insurance
Insurance
Prepaid and other current assets.
Prepaid And Other Current Assets [Abstract]
Issuance of Common Stock and Pre Funded Warrants Of Public Offering Net of Issuance Costs
Issuance of Common Stock and Pre Funded Warrants Of Public Offering Net of Issuance Costs
Issuance of common stock and pre-funded warrants in connection with June 2026 public offering, net of issuance costs
Issuance of Common Warrants and Placement Agent Warrants.
Issuance Of Common Warrants And Placement Agent Warrants
Issuance of 2023 Common Warrants and Placement Agent Warrants
Maximum [Member]
Maximum [Member]
Statistical Measurement [Axis]
Statistical Measurement
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Exercised
Common Stock, Value, Issued
Common stock, $0.01 par value per share, 100,000,000 and 500,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively, 4,036,398 and 435,432 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Warrants and Rights Outstanding
Return for a pre-funded warrant
Pre Funded Common Warrants
Pre Funded Common Warrants
Additional cash and cash equivalent and available for sale debt securities.
Additional Cash And Cash Equivalent And Available For Sale Debt Securities
Additional cash and cash equivalent and available for sale debt securities
September 2023 Warrants [Member]
September 2023 Warrants [Member]
September 2023 Warrants
Preferred Stock, Shares Authorized
Preferred Stock, shares authorized
Business combination, recognized identifiable assets acquired and liabilities assumed, operating lease right-of-use asset.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Asset
Operating lease right-of-use asset
Mergers, Acquisitions and Dispositions Disclosures [Text Block]
Merger Accounting
Business Combination [Table]
Schedule Of Business Acquisitions By Acquisition [Table]
Entity Registrant Name
Entity Registrant Name
Debt Disclosure [Text Block]
Debt
Other Nonoperating Income (Expense)
Total other expense, net
Total other expense, net
Other expense, net
Other expense, net
Qualified cash balance
Qualified cash balance
Subsequent Events [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]
Schedule of Other (income) expense, net
Cash and cash equivalent and available for sale debt securities.
Cash And Cash Equivalent And Available For Sale Debt Securities
Cash, cash equivalents and marketable securities
Proceeds from research and development grants.
Proceeds From Research And Development Grants
R&D grants received
Measurement Frequency [Axis]
Change in fair value of Common Warrants and Placement Agent Warrants
Change in fair value of Common Warrants and Placement Agent Warrants
Change in fair value of warrant liabilities
Proceeds from Issuance of Common Stock
Proceeds from sale of common stock, net of issuance costs
Sale of common stock through ATM, net of issuance costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Summary of the fair value of the derivative liabilities
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Other Income and Other Expense Disclosure [Text Block]
Other (Income) Expense, Net
Consolidation Items [Axis]
Hercules term loan agreement.
Hercules Term Loan Agreement [Member]
Hercules Term Loan Agreement [Member]
Funding award amount received.
Funding Award Amount Received
Funding award amount received
Loan, prepayment fee percentage
Debt Instrument Prepayment Fee Percentage
Debt instrument prepayment fee percentage.
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Granted
Proceeds From The Issuance of Common Stock, Pre-Funded Warrants, And Common Stock Warrants
Proceeds From The Issuance of Common Stock, Pre-Funded Warrants, And Common Stock Warrants
Proceeds from issuance of pre-funded warrants under the Coastlands and Domicilium Securities Purchase Agreements, net of issuance costs
Accrued interest on debt
Deposit Liabilities, Accrued Interest
Assets
Total assets
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Options exercisable
Income Statement [Abstract]
Issuance of Common Stock and Pre Funded Warrants Of Public Offering Net of Issuance Costs, Shares
Issuance of Common Stock and Pre Funded Warrants Of Public Offering Net of Issuance Costs, Shares
Issuance of common stock and pre-funded warrants in connection with June 2026 public offering, net of issuance costs. Shares
SVB Warrants [Member]
SVB Warrants [Member]
SVB Warrants
Stock Issued During Period, Shares, New Issues
Issuance of shares upon public offering, shares
Sale of common stock through ATM, net of issuance costs, Share
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Vested
Vested
Business Combination [Abstract]
Earnings Per Share, Diluted
Net loss per share, diluted
Net loss per share, diluted
Earnings Per Share, Diluted, Total
Debt Conversion, Original Debt, Amount
Domicilium debt conversion and waiver of accrued interest, (principal of $1,000 and accrued interest of $56
Operating Segments [Member]
Operating Segments [Member]
Percentage of sale or license event.
Percentage Of Sale Or License Event
Percentage of sale or license event
Title and Position [Domain]
City Area Code
City Area Code
Aggregate offering price.
Aggregate Offering Price
Aggregate offering price
Business Combination [Line Items]
Business Acquisition [Line Items]
Reconciliation of cash, cash equivalents and restricted cash to condensed consolidated balance sheets.
Reconciliation Of Cash Cash Equivalents And Restricted Cash To Condensed Consolidated Balance Sheets [Abstract]
Reconciliation of cash, cash equivalents and restricted cash to condensed consolidated balance sheets:
Business combination, recognized identifiable assets acquired and liabilities assumed noncurrent operating lease liability.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Operating Lease Liability
Operating lease liability
Coastlands Securities Purchase Agreement [Member]
Coastlands Securities Purchase Agreement [Member]
Coastlands Securities Purchase Agreement [Member]
Common Stock, Public Offering Price Per Share
Common Stock, Public Offering Price Per Share
Public Offering Price Per Share
Segment Reporting Information [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Vesting of restricted stock awards shares
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate
Loan, interest rate
Business Combination, Consideration Transferred, Equity Interest
Fair value of common stock consideration
Almirall License Agreement [Member]
Almirall License Agreement Member
Almirall License Agreement [Member]
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Cash, cash equivalents and restricted cash at the end of the period
Cash, cash equivalents and restricted cash at the beginning of the period
Total cash, cash equivalents and restricted cash
Total cash, cash equivalents and restricted cash
Operating Income (Loss)
Loss from operations
Loss from operations
Loan, principal amount percentage
Debt Instrument Principal Amount Percentage
Debt instrument principal amount percentage.
Retained Earnings [Member]
Accumulated deficit [Member]
Cash and Cash Equivalents [Axis]
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense, Total
Payments of Stock Issuance Costs
Issuance cost
Outstanding principal value
Short-Term Debt, Average Outstanding Amount
Repayments of Construction Loans Payable
Repayments of bridge loans payable
Other (income) expense
Other Nonoperating Expense
Other expense
Fair Value, Inputs, Level 1 [Member]
Level 1 [Member]
Class of Stock [Line Items]
Class Of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by (used in) financing activities
Common Stock Exercise Price
Common Stock Exercise Price
Common stock exercise price
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding
Entity Interactive Data Current
Entity Interactive Data Current
Statement of Income Location, Balance [Domain]
Income Statement Location
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Cash flows from operating activities:
Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares
Number of shares issued in Merger Agreement
Tranche 1 Advance [Member]
Tranche One Advance [Member]
Tranche one advance.
Entity Tax Identification Number
Entity Tax Identification Number
Weighted average share price
Share Price
Actual closing price per share of Company common stock as reported on the Nasdaq Capital Market on April 1, 2021
Repayments of Notes Payable
Repayment of term loan principal
Long-Term Debt, Type [Axis]
Long-Term Debt, Type
Stock Subscription Receivable [Member]
Stock Subscription Receivable [Member]
Two Thousand Twenty Five Bridge Loans [Member]
Two Thousand Twenty Five Bridge Loans [Member]
Bridge Loan [Member]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Nature of the Business
Local Phone Number
Local Phone Number
Related Party Transaction [Domain]
Business combination, recognized identifiable assets acquired and liabilities assumed current operating lease liability.
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Operating Lease Liability
Current portion of operating lease liability
Board of Directors Chairman [Member]
Common Stock Upon Conversion of Warrant Exercise Shares
Common Stock Upon Conversion of Warrant Exercise Shares
Common stock upon conversion of warrant exercise shares
Domicilium [Member]
Domicilium Member
Sale of common stock through ATM, net of issuance costs
Issuance cost
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Accounting Policies [Abstract]
March Two Thousand Twenty Six Pre Funded Warrant [Member]
March Two Thousand Twenty Six Pre Funded Warrant [Member]
March 2026 Pre-Funded Warrants
Imputed Interest on Bridge Loans
Imputed Interest on Bridge Loans
Imputed interest expense on 2025 bridge loans
Prepaid expenses and other current assets.
Prepaid Expenses And Other Current Assets [Text Block]
Prepaid Expenses and Other Current Assets
Accrued Professional Fees, Current
Professional services
Stock, Class of Stock [Table]
Schedule Of Stock By Class [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill
Purchase price